Recent years have seen notable advancements in cancer immunotherapy, specifically through the utilization of immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1) and its ligand (PD-L1), offering hope to many patients with advanced cancer (1). The gene discussed is CD274; the disease is cancer.